Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer’s Disease Conference (CTAD)